Yes, she should start at the lowest dose (2.5 mg weekly)
When switching from Ozempic (semaglutide) 1 mg to Mounjaro (tirzepatide), patients should begin with the 2.5 mg starting dose and titrate upward monthly, regardless of their previous GLP-1 RA dose. This approach minimizes gastrointestinal side effects and allows the body to acclimate to the new medication mechanism.
Rationale for Starting at 2.5 mg
The FDA-approved dosing for tirzepatide mandates initiation at 2.5 mg weekly, with monthly escalation to 5 mg, then 10 mg, and finally 15 mg as needed 1. This titration schedule applies universally—even when switching from other GLP-1 receptor agonists like semaglutide.
The most recent AACE guidelines (2025) explicitly state that "starting with the lowest dose is essential to prevent clinically significant side effects, and slow dose up-titration is vital in mitigating potential side effects" 2. The guidelines emphasize that patients who discontinue or pause treatment need to restart at a low dose and titrate up to enable the body time to acclimate to the medication 2.
Why Not Start Higher?
While tirzepatide is a dual GIP/GLP-1 receptor agonist (versus semaglutide's selective GLP-1 action), the additional GIP receptor mechanism introduces different pharmacodynamics that require gradual introduction. The gastrointestinal side effects—nausea, vomiting, diarrhea—occur most commonly during dose escalation and are the primary reason for the conservative titration approach 2, 3.
Evidence on Direct Switching
Recent research provides nuanced insights:
A 2024 prospective study showed that switching directly from various GLP-1 RAs (including semaglutide 1.0 mg) to tirzepatide 5 mg resulted in improved glycemic control (HbA1c reduction of -0.43%) and additional weight loss (-2.15 kg) over 12 weeks, with acceptable tolerability (13.2% gastrointestinal events, 2% discontinuation) 4
However, a 2025 retrospective study suggested that early escalation to 10 mg (rather than stopping at 7.5 mg) after the initial 2.5 mg dose may provide better glycemic improvement when switching from semaglutide 1.0 mg 5
Despite this emerging data suggesting tolerability of higher starting doses in some patients, the FDA label and current guidelines do not support bypassing the 2.5 mg starting dose 1.
Practical Titration Strategy
- Week 0-4: Start tirzepatide 2.5 mg weekly
- Week 4-8: Increase to 5 mg weekly
- Week 8-12: Increase to 10 mg weekly (if additional glycemic control or weight loss needed)
- Week 12+: Increase to 15 mg weekly (if maximal effect desired)
The therapeutic doses are 5 mg, 10 mg, and 15 mg weekly—the 2.5 mg dose serves primarily as a tolerability step 2.
Mitigating Side Effects During Transition
- Counsel patients to avoid fatty foods, not eat past fullness, and consume smaller portions more frequently 2
- Monitor for dehydration if vomiting or diarrhea occurs 3
- Adjust any concurrent sulfonylureas or insulin to prevent hypoglycemia 3
- Set expectations that gastrointestinal symptoms are typically transient and improve with continued therapy 6
Common Pitfall to Avoid
Do not assume that because the patient tolerated semaglutide 1 mg well, she can skip the 2.5 mg tirzepatide dose. The dual receptor mechanism and different pharmacokinetic profile (half-life 116.7 hours for tirzepatide vs. approximately 7 days for semaglutide) necessitate the standard titration protocol 2.